

Supplementary Tables for "Buprenorphine dose and urinalysis:
analysis of individual participant data"

Andrew W Bergen, James W Baurley, Carolyn M Ervin, Christopher S McMahan, Joe
Bible, Randall Stafford, Sesh Mudumbai, Andrew Saxon

List of Tables

1	Study Data Downloaded from NIDA Data Share Website in mid-2017.	3
2	Studies with Individual Patient Data Analyzed in This Study.	4
3	Study Inclusion Criteria	5
4	Study Exclusion Criteria (CSP-999, CSP-1008A, CSP-1008B, CSP-1018) . .	6
5	Study Exclusion Criteria (CTN-0027, CTN-0030)	7
6	Study Designs of the Six Clinical Trials Analyzed*	8
7	Demographics of Screened Individuals in the Six Trials	9
8	Sociodemographic Characteristics of the Analysis Dataset	10
9	Drug Use History Characteristics of the Analysis Dataset	12
10	Single Example of Daily Dose, Urinalysis Days, and Time-Weighted Dose . .	13
11	Treatment Trials: Inclusion in Prior Analyses and Systematic Reviews	14
12	PubMed Searches (Most Recent), Treatment Variable Related Terms	15

Table 1: Study Data Downloaded from NIDA Data Share Website in mid-2017.

Division	Study Number	Title	Investigators	Release Date
DTMC	CSP-999	A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence	Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D.	Sep 02, 2015
DTMC	CSP-1008A	A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Peter Bridge, M.D., Paul J. Fudala, Ph.D.	Dec 04, 2014
DTMC	CSP-1008B	A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Peter Bridge, M.D.	Dec 04, 2014
DTMC	CSP-1018	A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D.	Sep 02, 2015
CTN	CTN-0001	Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification	Walter Ling, M.D.	May 08, 2006
CTN	CTN-0002	Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification	Walter Ling, M.D.	Jul 26, 2006
CTN	CTN-0003	Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Two Schedules	Walter Ling, M.D.	May 29, 2008
CTN	CTN-0027	Starting Treatment with Agonist Replacement Therapies (START)	Walter Ling, M.D.	Jul 30, 2009
CTN	CTN-0030	A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence	Walter Ling, M.D., Roger Weiss, M.D.	Jun 22, 2011
CTN	CTN-0030A3	Long-Term Follow-Up to CSP-0030 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence)	Roger Weiss, M.D., Jennifer Sharpe Potter, Ph.D.	Aug 22, 2014

Table 2: Studies with Individual Patient Data Analyzed in This Study.

Division	Study Number	Title	Investigators	Release Date
DTMC	CSP-999	A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence	Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D.	Sep 02, 2015
DTMC	CSP-1008A	A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Peter Bridge, M.D., Paul J. Fudala, Ph.D.	Dec 04, 2014
DTMC	CSP-1008B	A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Peter Bridge, M.D.	Dec 04, 2014
DTMC	CSP-1018	A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence	Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D.	Sep 02, 2015
CTN	CTN-0027	Starting Treatment with Agonist Replacement Therapies (START)	Walter Ling, M.D.	Jul 30, 2009
CTN	CTN-0030	A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Individual Drug Counseling for Opioid Analgesic Dependence	Walter Ling, M.D., Roger Weiss, M.D.	Jun 22, 2011

Table 3: Study Inclusion Criteria

Study	Inclusion Criteria*
CSP-999	M/F (non-pregnant, non-nursing), ages 21-50. Current opiate dependence according to DSM-III-R/DSM-IV criteria with daily use for past month. Agreeable to conditions of the study and signs informed consent. Resident within commuting distance of clinic. Urine negative for methadone.
CSP-1008A	Males and females (non-pregnant, non-nursing), ages 18-59 inclusive. Current opiate dependence according to DSM-IV criteria. Treatment seeking. Agreeable to conditions of the study and able to give informed consent.
CSP-1008B	Males and females (non-pregnant, non-nursing), ages 18-59 inclusive. Current opiate dependence according to DSM-IV criteria. Treatment seeking. Agreeable to conditions of the study and able to give informed consent.
CSP-1018	M/F (non-pregnant, non-nursing), at least 15 years of age. Current opiate dependence according to DSM-IV criteria. Treatment seeking with the desire to discontinue opiate use as an initial goal but willing to consider and accept longer treatment if necessary. Be in good physical health, or in the care of a physician for medical or psychiatric treatment. Agreeable to conditions of the study and able to give informed consent.
CTN-0027	Males and females (non-pregnant, non-nursing), at least 18 years of age. Current opiate dependence according to DSM-IV-TR criteria. Treatment seeking. Agreeable to conditions of the study and able to give informed consent.
CTN-0030	Males and females at least 18 years of age, treatment seeking (detoxification), and meet DSM-IV criteria for current prescription opioid dependence (≥ 20 days/month). Without chronic pain severe enough to require ongoing opioid therapy or an acute pain event within the past six months. Medically stable and psychiatrically stable in the opinion of the study investigator. Good general health, or, for patients receiving ongoing medical or psychiatric treatment, participant's physician must be willing to continue management and cooperate with study physicians. Participants receiving opioids for pain must have clearance from their prescribing physician to enter the trial; the study physician will consult to ensure that the participant is medically stable enough to enter the trial. Participants who use prescription opioids by injection may be included as long as they have never injected heroin. Agreeable to conditions of the study and able to give informed consent.

*From clinicaltrials.gov and datashare.nida.nih.gov protocols. Some rewording to enhance comparisons.

Table 4: Study Exclusion Criteria (CSP-999, CSP-1008A, CSP-1008B, CSP-1018)

Study	Exclusion Criteria*
CSP-999	Any acute medical condition that would make participation in the study medically hazardous for the patient, with extra monitoring and hepatologist consultation where liver enzymes are > 5 and > 8 times upper limit of normal, respectively. DSM-III-R diagnosis of current alcohol dependence or sedative-hypnotic dependence. Current daily use of anticonvulsants, Antabuse, or neuroleptics. Expected inability to complete study. Enrollment in a methadone maintenance program within past 30 days. Participation in another research project. Female of childbearing potential who refuses birth control.
CSP-1008A	Any acute medical condition that would make participation in the study medically hazardous for the patient. Liver enzyme levels > 3 times upper limit of normal. Current use of systemic anti-retroviral or anti-fungal therapy. DSM-IV diagnosis of any psychoactive substance dependence other than opiate, caffeine, or nicotine dependence. Licit or illicit use of methadone, LAAM or naltrexone within the last days. Use of buprenorphine, other than as an analgesic, within the last 365 days. Expected inability to complete study. Enrollment in a methadone or LAAM maintenance program within past 45 days. Female of childbearing potential who refuses birth control.
9 CSP-1008B	Any acute medical condition that would make participation in the study medically hazardous for the patient. Liver enzyme levels > 3 times upper limit of normal. Current use of systemic anti-retroviral or anti-fungal therapy. DSM-IV diagnosis of any psychoactive substance dependence other than opiate, caffeine, or nicotine dependence. Licit or illicit use of methadone, LAAM or naltrexone within the last days. Use of buprenorphine, other than as an analgesic, within the last 365 days. Expected inability to complete study. Enrollment in a methadone or LAAM maintenance program within past 45 days. Female of childbearing potential who refuses birth control.
CSP-1018	Any acute medical condition that would make participation in the study medically hazardous for the patient, with hepatologist consultation where liver enzymes are > 8 times upper limit of normal. Known sensitivity to buprenorphine or naloxone. Acutely psychotic, severely depressed or an immediate suicide risk. Dependence upon alcohol, benzodiazepines or other drugs of abuse (excluding tobacco) requiring immediate medical attention. Participation in an investigational drug study within the past 30 days. Discontinued participation in a methadone or LAAM treatment program within the past 30 days. Licit or illicit use of methadone, LAAM or naltrexone for more than 30 days before enrolling in this study. Female of childbearing potential who refuses birth control. Expected inability to complete study.

*From clinicaltrials.gov and datashare.nida.nih.gov protocols. Some rewording to enhance comparability.

Table 5: Study Exclusion Criteria (CTN-0027, CTN-0030)

Study	Exclusion Criteria*
CTN-0027	Any acute medical condition that would make participation in the study medically hazardous for the patient. Liver enzymes (either) > 5 times upper limit of normal. Alkaline phosphatase > 3 times upper limit of normal. Model for Endstage Liver Disease score ≥ 11 . Total bilirubin ≥ 2 mg/dl, albumin ≤ 2.5 g/dl or prothrombin time ≥ 3 seconds. Participants with cardiac risk factors as confirmed by abnormal ECGs. Known sensitivity to buprenorphine, methadone, naloxone or any study medication ingredient. Diagnosis of acute psychosis, severe depression or an immediate suicide risk. DSM-IV dependence upon alcohol, benzodiazepines, other depressants or stimulants, requiring medical immediate attention or likelihood of intravenous misuse by past history of intravenous use. Participation in an investigational drug study within the past 30 days. Treatment with methadone, buprenorphine, buprenorphine/naloxone, for ≥ 15 of the past 30 days (illicit use is not an exclusion). Female of childbearing potential who refuses birth control. Expected inability to complete study. Poor venous access.
CTN-0030	Any medical condition that would make participation in the study medically hazardous for the patient, in the opinion of the study investigator/physician, based on a review of medical records and baseline evaluations. Known sensitivity to buprenorphine, or naloxone. Diagnosis of acute psychosis, severe depression, or a suicide risk within the past 30 days. DSM-IV dependence upon alcohol, sedative-hypnotics or stimulants, and requiring medical immediate attention. Currently receiving formal substance abuse treatment. Have used heroin ≥ 4 days in the past 30 days. Lifetime opioid dependence accounted for by heroin use only. Have ever used heroin by injection. Have experienced a traumatic or major pain event within the past six months. Participation in another investigational drug study within the past 30 days. Participated in methadone or buprenorphine maintenance treatment for opioid dependence within 30 days of study enrollment. Female of childbearing potential who refuses birth control. Expected inability to complete study due to residence change or scheduled surgery. Pain of sufficient severity as to require ongoing pain management with opioids.

*From clinicaltrials.gov and datashare.nida.nih.gov protocols. Some rewording to enhance comparability.

Table 6: Study Designs of the Six Clinical Trials Analyzed*

Trial	CSP-999	CSP-1008A	CSP-1008B	CSP-1018	CTN-0027	CTN-0030
Years, Start-End	'92-'97	'96-'97	'96-'97	'99-'02	'06-'10	'06-'09
Allocation	Randomized	Randomized	Non-randomized	Non-Randomized	Randomized	Randomized
Intervention	Parallel	Mixed	Single group	Single group	Parallel	Parallel
Masking	Double blind	Mixed	Open label	Open label	Open label	Open label
Phases	Two	Two	One	One	One	Two
Purpose	Safety/Efficacy	Efficacy/Safety ^α	Safety	Efficacy ^β	Safety	Efficacy
Tx length max (mo)	12	12	12	12	8	8
Tx Phase One (wk)	40	4	52	52	24-32	4 Rx, 8 Counseling
∞ Rx ^γ Phase One	B	B:B/N:P	B/N	B/N	B/N, M	B/N
Rx Dose (g/d) Phase One	1:4:8:16	16:16/4,P	Per physician	Per physician	Per physician	Per physician
Psychosocial Phase One	1-4 hr/mo	1 hr/wk	≥ 1hr/wk	0.5 hr/wk	Per clinic	0.4:1.3 hr/wk ^δ
Tx Phase Two (wk)	12	48	-	-	-	16
Rx Phase Two	B	B/N	-	-	-	B/N
Rx Dose Phase Two	Per physician	Per physician	-	-	-	Per physician
Psychosocial Phase Two	1 hr/wk	≥ 1hr/wk	-	-	-	0.3:1.2 hr/wk
Urinalysis as Outcome	Primary ^ε	Primary	Secondary	Primary	Secondary	Primary

*From clinicaltrials.gov and datashare.nida.nih.gov. ^αFor Phase One, and Safety for Phase Two. ^βFor adult participants, and safety, efficacy, and feasibility of detoxification, then maintenance per clinical judgement in participants 15 to 20 years of age. ^γRx: B=buprenorphine, B/N=buprenorphine/naloxone, P=placebo, M=methadone. ^δStandard Medical Management *vs* Enhanced Medical Management, aka Opioid Drug Counseling (Weiss et al. 2011). ^εSelf-reported lapse.

Table 7: Demographics of Screened Individuals in the Six Trials

Trial	CSP-999	CSP-1008A	CSP-1008B	CTN-1018	CTN-0027	CTN-0030	Overall
Totals	(N = 736)	(N = 449)	(N = 282)	(N = 596)	(N = 1920)	(N = 870)	(N = 4853)
Age (Years)							
Mean (SD)	36.0 (7.8)	37.6 (8.9)	40.0 (7.7)	35.8 (10.5)	37.4 (11.1)	33.2 (10.2)	36.33 (10.6)
Min, Max	(18, 67)	(19, 60)	(19, 59)	(15, 66)	(18, 68)	(18, 77)	(18, 77)
Missing (n, %)	2 (0.3)	123 (27.4)	77 (27.3)	29 (4.9)	651 (33.1)	216 (24.8)	1098 (22.6)
Gender, n (%)							
Male	497 (67.5)	290 (64.7)	72 (71.6)	394 (66.1)	1285 (67.0)	524 (60.3)	3192 (65.8)
Female	239 (32.5)	158 (35.3)	28 (28.4)	202 (33.9)	632 (33.0)	345 (39.7)	1656 (34.2)
R/Eth, n (%)							
W, Non-His	359 (48.8)	257 (57.4)	115 (40.8)	437 (73.4)	1243 (64.7)	751 (86.3)	3162 (65.2)
B, Non-His	161 (21.9)	136 (30.4)	94 (33.3)	46 (7.7)	212 (11.0)	30 (3.4)	679 (14.0)
Nat Amer	5 (0.7)	4 (0.9)	0 (0.0)	7 (1.2)	65 (3.4)	16 (1.8)	97 (2.0)
As/Pac Is	4 (0.5)	8 (1.8)	2 (0.7)	11 (1.8)	36 (1.9)	4 (0.5)	65 (1.3)
Hispanic	207 (28.1)	43 (9.6)	71 (25.2)	94 (15.8)	329 (17.1)	42 (4.8)	786 (16.2)
Other	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	35 (1.8)	27 (3.1)	62 (1.3)
Missing	0 (0.0)	1 (0.2)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)	2 (0.004)

Table 8: Sociodemographic Characteristics of the Analysis Dataset

Age	Mean	SD
	36.14	9.84
Gender	N	%
Men	2017	67
Women	1005	33
Race	N	%
White	2001	66
Black	422	14
American Indian	50	2
Asian	48	2
Hispanic	495	16
Other	6	< 1
Education	N	%
Complete Graduate School	89	3
Standard College	213	7
Partial College	829	27
High School	1456	48
Partial High School	304	10
Junior High School	116	4
Less than 7th grade	15	< 1
WorkType	N	%
Fulltime	1758	58
Regular PT	232	8
Irregular PT	284	9
Student	64	2
Military	1	< 1
Retired	84	3
Unemployed	582	19
Controlled	17	1
Employment History	N	%
Never Gainfully	653	22
Unskilled	235	8
Machine Operator	445	15
Skilledmanual	889	29
Clerical/Sales	407	13
Administrative	239	8
Business Manager	101	3
Executive	53	2
Income	Mean	SD
	20834	30024

Continuation of Table 8

MaritalStatus	N	%
Married	1038	34
Remarried	20	1
Widowed	39	0.01
Seperated	261	9
Divorced	602	20
Never Married	1014	34
LivingArr	N	%
Partner and Child	1251	41
Partner Only	537	18
Child Only	183	6
Parents	294	10
Family	263	9
Friends	255	8
Alone	190	6
Controlled	25	1
No Stable	24	1
End of table		

Table 9: Drug Use History Characteristics of the Analysis Dataset

Variable	N or Mean	% or SD
Heroin and opioid use		
Heroin use	2354	78
No heroin use	668	22
Years of opiate/opioid use	8.23	8.41
Primary mode of opiate/opioid use		
Oral	122	4
IV	1710	57
Snort	1089	36
Smoking	74	2
Sublingual	5	< .01
Other	22	1
Cocaine use		
YES	1837	61
NO	1185	39
Methamphetamine use		
YES	718	24
NO	2304	76
Alcohol use		
YES	1891	63
NO	1131	37
Tranquilizer use		
YES	1025	34
NO	1997	66
Marijuana use		
YES	1953	65
NO	1069	35
Phencyclidine use		
YES	477	16
NO	2545	84

Table 10: Single Example of Daily Dose, Urinalysis Days, and Time-Weighted Dose

Variable	Data
Daily Dose	8 16 24 24 32 0 0 32 0 32 32 32 0 32 32 0 32 32 32 32 32 32 32 32 30 30 30 30 30 30 30 30 32 30 30 30 30 0 32 30 30 30 30 30 30 30 30 30 30 30 30 26 26 26 28 28 28 28 28 28 28 24 26 26 26 26 22 0 24 24 24 24 24 24
Urinalysis Days	7 17 23 35 41 52 56 64 72 79 93 101 108 122 128 136 143 149 158 163 171
Time Weighted Dose	29.58730 31.99768 31.99996 32.00000 16.00000 31.97656 31.99854 31.99999 31.00000 31.74219 23.93748 31.71851 31.99780 30.06274 29.59473 29.99842 29.99999 30.00000 27.95312 25.99854 23.62499

Table 11: Treatment Trials: Inclusion in Prior Analyses and Systematic Reviews

Study and NCT ID	Trial Description	Secondary Data Analyses	Meta-analysis or Systematic Review*
CSP-999 0000000207	Ling et al. 1998	-	Mattick et al. 2014; Simoens et al. 2005
CSP- 1008A 0000015028	Fudala et al. 2003	-	Mattick et al. 2014; Maglione et al. 2018
CSP- 1008B 0000015171	Fudala et al. 2003	-	Mattick et al. 2014; Maglione et al. 2018
CSP-1018 0000007527	Fudala et al. 2006	-	-
CTN-0027 0000315341	Saxon et al. 2013b	Ling et al. 2010; Tai et al. 2011; Crist et al. 2013; Potter et al. 2013; Saxon et al. 2013a; Clarke et al. 2014; Hser et al. 2014; Teruya et al. 2014; Woody et al. 2014; Jacobs et al. 2015; Schulte et al. 2015; Hser et al. 2016; Ali et al. 2017; Hser et al. 2017; Chang et al. 2017; Zhu et al. 2018; Crist et al. 2018b,a; Evans et al. 2019a,b	Nielsen et al. 2016
CTN-0030 0000316277	Potter et al. 2010; Weiss et al. 2010a,b, 2011	Ling et al. 2010; Upadhyay et al. 2010; Potter et al. 2011; Tai et al. 2011; Dreifuss et al. 2013; McHugh et al. 2013; Nielsen et al. 2013; Griffin et al. 2014; Meade et al. 2014; McHugh et al. 2014; Weiss et al. 2014; Hilario et al. 2015; Weiss et al. 2015; Worley et al. 2015a; McDermott et al. 2015; Northrup et al. 2015; Potter et al. 2015; Worley et al. 2015a,b; Griffin et al. 2016; Lindblad et al. 2016; Weiss and Rao 2017; Wor- ley et al. 2017; Weiss et al. 2019	Carroll and Weiss 2017

Sources: datashare.nida.nih.gov, clinicaltrials.gov, ctndisseminationlibrary.org, ncbi.nlm.nih.gov/pubmed, and PubMed searches using terms "buprenorphine", "meta-analysis", and "systematic review". *Mattick et al. 2014, Maglione et al. 2018, and Nielsen et al. 2016 used summary data and a random effects model. Simoens et al. 2005 and Carroll and Weiss, 2017 used a descriptive review approach.

Table 12: PubMed Searches (Most Recent), Treatment Variable Related Terms

Search Terms	Records Returned	Linked Literature	Variable Model
Time-weighted dose AND buprenorphine	No records		
" AND methadone	No records		
" AND naltrexone	No records		
" AND opioid agonist	No records		
" AND medication assisted treatment	No records		
" AND substance use disorder treatment	One record	Rumack-Matthew acetaminophen overdose nomogram using 4 hour half-life	Log
" AND medication	38 records. Reviewed 25 records.	Medical (23/25), and toxicological (2/25). Time-weighted variable most often an outcome (24/25), one covariate (1/25). Outcomes are most often pain scores (17/23 medical records) and toxicant exposures (2/25).	Linear
Time-weighted AND clinical dose	One record	COX-2 inhibition assays (outcome)	Linear
" AND clinical dose adjustment	3 records	Clinical biomarkers and <i>in vitro</i> bioassays	Linear
" AND clinical engagement	One record	Ecotoxicology review of time-weighted averaging, body-burden models and expert judgment	Linear
" AND clinical judgement	No records		
" AND clinical impression	No records		
" AND patient engagement	No records		
" AND patient visit	3 records	Outcomes: surgery times, post-operative requirements, and disability scores	Linear
" AND self-administered dose	No records		
" AND self-administered	8 records	Mostly (6/8) toxicological. Time-weighted variable an exposure value.	Linear
Time in Trial AND predictor AND buprenorphine	7 records	Trials but time in trial not predictor of BUP MOUD outcome	

References

- Ali, S., Tahir, B., Jabeen, S., Malik, M., Jul. 2017. Methadone treatment of opiate addiction: A systematic review of comparative studies. *Innov. Clin. Neurosci.* 14 (7-8), 8–19.
- Carroll, K. M., Weiss, R. D., Aug. 2017. The role of behavioral interventions in buprenorphine maintenance treatment: A review. *Am. J. Psychiatry* 174 (8), 738–747.
- Chang, K.-C., Wang, J.-D., Saxon, A., Matthews, A. G., Woody, G., Hser, Y.-I., May 2017. Causes of death and expected years of life lost among treated opioid-dependent individuals in the united states and taiwan. *Int. J. Drug Policy* 43, 1–6.
- Clarke, T.-K., Crist, R. C., Ang, A., Ambrose-Lanci, L. M., Lohoff, F. W., Saxon, A. J., Ling, W., Hillhouse, M. P., Bruce, R. D., Woody, G., Berrettini, W. H., Jun. 2014. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. *Pharmacogenomics J.* 14 (3), 303–308.
- Crist, R. C., Clarke, T.-K., Ang, A., Ambrose-Lanci, L. M., Lohoff, F. W., Saxon, A. J., Ling, W., Hillhouse, M. P., Bruce, R. D., Woody, G., Berrettini, W. H., Sep. 2013. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. *Neuropsychopharmacology* 38 (10), 2003–2010.
- Crist, R. C., Doyle, G. A., Nelson, E. C., Degenhardt, L., Martin, N. G., Montgomery, G. W., Saxon, A. J., Ling, W., Berrettini, W. H., Jan. 2018a. A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. *Pharmacogenomics J.* 18 (1), 173–179.
- Crist, R. C., Li, J., Doyle, G. A., Gilbert, A., Dechairo, B. M., Berrettini, W. H., Jan. 2018b. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. *Am. J. Drug Alcohol Abuse* 44 (4), 431–440.
- Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J., Hatch-Maillette, M., Sonne, S. C., Weiss, R. D., Jul. 2013. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. *Drug Alcohol Depend.* 131 (1-2), 112–118.
- Evans, E. A., Yoo, C., Huang, D., Saxon, A. J., Hser, Y.-I., Nov. 2019a. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. *J. Subst. Abuse Treat.* 106, 19–28.
- Evans, E. A., Zhu, Y., Yoo, C., Huang, D., Hser, Y.-I., Aug. 2019b. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. *Addiction* 114 (8), 1396–1404.
- Fudala, P., Walsh, R., Ling, W., Casadonte, P., McSherry, F., Williford, W., Collins, J., Raisch, D., Kilby, S., Saxon, A., Johnson, B., Ordorica, P., Malkerneker, U., Elkashef, A., 2006. Office-Based treatment of opioid dependence with Buprenorphine/Naloxone sublingual tablets: Results from a multicenter study. In: Dewey, W. L. (Ed.), 67th Annual Meeting of College on Problems of Drug Dependence. NIDA Research Monograph. NIDA, NIH, HHS, Bethesda.
- Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., Tusel, D., Buprenorphine/Naloxone Collaborative Study Group, Sep. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N. Engl. J. Med.* 349 (10), 949–958.
- Griffin, M. L., Dodd, D. R., Potter, J. S., Rice, L. S., Dickinson, W., Sparenborg, S., Weiss, R. D., Mar. 2014. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. *Am. J. Drug Alcohol Abuse* 40 (2), 157–162.
- Griffin, M. L., McDermott, K. A., McHugh, R. K., Fitzmaurice, G. M., Jamison, R. N., Weiss, R. D., Jun. 2016. Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain. *Drug Alcohol Depend.* 163, 216–221.
- Hilario, E. Y., Griffin, M. L., McHugh, R. K., McDermott, K. A., Connery, H. S., Fitzmaurice, G. M., Weiss, R. D., Jan. 2015. Denial of urinalysis-confirmed opioid use in prescription opioid dependence. *J. Subst. Abuse Treat.* 48 (1), 85–90.

- Hser, Y.-I., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch-Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., Ling, W., Apr. 2016. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. *Addiction* 111 (4), 695–705.
- Hser, Y.-I., Huang, D., Saxon, A. J., Woody, G., Moskowitz, A. L., Matthews, A. G., Ling, W., 2017. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. *J. Addict. Med.* 11 (1), 63–69.
- Hser, Y.-I., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., Cohen, A., Ling, W., Jan. 2014. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. *Addiction* 109 (1), 79–87.
- Jacobs, P., Ang, A., Hillhouse, M. P., Saxon, A. J., Nielsen, S., Wakim, P. G., Mai, B. E., Mooney, L. J., S Potter, J., Blaine, J. D., Oct. 2015. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. *Am. J. Addict.* 24 (7), 667–675.
- Lindblad, R., Hu, L., Oden, N., Wakim, P., Rosa, C., VanVeldhuisen, P., Nov. 2016. Mortality rates among substance use disorder participants in clinical trials: Pooled analysis of Twenty-Two clinical trials within the national drug abuse treatment clinical trials network. *J. Subst. Abuse Treat.* 70, 73–80.
- Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, Jr, L. S., Kintaudi, P., Wesson, D. R., McNicholas, L., Tusel, D. J., Malkerneker, U., Renner, Jr, J. A., Santos, E., Casadonte, P., Fye, C., Stine, S., Wang, R. I., Segal, D., Apr. 1998. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. *Addiction* 93 (4), 475–486.
- Ling, W., Jacobs, P., Hillhouse, M., Hasson, A., Thomas, C., Freese, T., Sparenborg, S., McCarty, D., Weiss, R., Saxon, A., Cohen, A., Straus, M., Brigham, G., Liu, D., McLaughlin, P., Tai, B., Jun. 2010. From research to the real world: buprenorphine in the decade of the clinical trials network. *J. Subst. Abuse Treat.* 38 Suppl 1, S53–60.
- Maglione, M. A., Raaen, L., Chen, C., Azhar, G., Shahidinia, N., Shen, M., Maksabedian, E., Shanman, R. M., Newberry, S., Hempel, S., Jun. 2018. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. *J. Subst. Abuse Treat.* 89, 28–51.
- Mattick, R. P., Breen, C., Kimber, J., Davoli, M., Feb. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst. Rev.* (2), CD002207.
- McDermott, K. A., Griffin, M. L., Connery, H. S., Hilario, E. Y., Fiellin, D. A., Fitzmaurice, G. M., Weiss, R. D., Feb. 2015. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. *J. Clin. Psychiatry* 76 (2), 189–194.
- McHugh, R. K., Devito, E. E., Dodd, D., Carroll, K. M., Potter, J. S., Greenfield, S. F., Connery, H. S., Weiss, R. D., Jul. 2013. Gender differences in a clinical trial for prescription opioid dependence. *J. Subst. Abuse Treat.* 45 (1), 38–43.
- McHugh, R. K., Fitzmaurice, G. M., Carroll, K. M., Griffin, M. L., Hill, K. P., Wasan, A. D., Weiss, R. D., Dec. 2014. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients. *Drug Alcohol Depend.* 145, 121–126.
- Meade, C. S., Bevilacqua, L. A., Moore, E. D., Griffin, M. L., Gardin, 2nd, J. G., Potter, J. S., Hatch-Maillette, M., Weiss, R. D., Jan. 2014. Concurrent substance abuse is associated with sexual risk behavior among adults seeking treatment for prescription opioid dependence. *Am. J. Addict.* 23 (1), 27–33.
- Nielsen, S., Hillhouse, M., Thomas, C., Hasson, A., Ling, W., Jan. 2013. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. *J. Addict. Med.* 7 (1), 33–38.
- Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., Lintzeris, N., May 2016. Opioid agonist treatment for pharmaceutical opioid dependent people. *Cochrane Database Syst. Rev.* (5), CD011117.
- Northrup, T. F., Stotts, A. L., Green, C., Potter, J. S., Marino, E. N., Walker, R., Weiss, R. D., Trivedi, M., Feb. 2015. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. *Addict. Behav.* 41, 20–28.
- Potter, J. S., Donovan, D. M., Weiss, R. D., Gardin, J., Lindblad, R., Wakim, P., Dodd, D., Sep. 2011. Site selection in community-based clinical trials for substance use disorders: strategies for effective site

- selection. *Am. J. Drug Alcohol Abuse* 37 (5), 400–407.
- Potter, J. S., Dreifuss, J. A., Marino, E. N., Provost, S. E., Dodd, D. R., Rice, L. S., Fitzmaurice, G. M., Griffin, M. L., Weiss, R. D., Jan. 2015. The multi-site prescription opioid addiction treatment study: 18-month outcomes. *J. Subst. Abuse Treat.* 48 (1), 62–69.
- Potter, J. S., Marino, E. N., Hillhouse, M. P., Nielsen, S., Wiest, K., Canamar, C. P., Martin, J. A., Ang, A., Baker, R., Saxon, A. J., Ling, W., Jul. 2013. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). *J. Stud. Alcohol Drugs* 74 (4), 605–613.
- Potter, J. S., Prather, K., Kropp, F., Byrne, M., Sullivan, C. R., Mohamedi, N., Copersino, M. L., Weiss, R. D., Mar. 2010. A method to diagnose opioid dependence resulting from heroin versus prescription opioids using the composite international diagnostic interview. *Contemp. Clin. Trials* 31 (2), 185–188.
- Saxon, A. J., Hser, Y.-I., Woody, G., Ling, W., Dec. 2013a. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. *J. Food Drug Anal.* 21 (4), S69–S72.
- Saxon, A. J., Ling, W., Hillhouse, M., Thomas, C., Hasson, A., Ang, A., Doraimani, G., Tasissa, G., Lokhnygina, Y., Leimberger, J., Bruce, R. D., McCarthy, J., Wiest, K., McLaughlin, P., Bilangi, R., Cohen, A., Woody, G., Jacobs, P., Feb. 2013b. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. *Drug Alcohol Depend.* 128 (1-2), 71–76.
- Schulte, M., Hser, Y., Saxon, A., Evans, E., Li, L., Huang, D., Hillhouse, M., Thomas, C., Ling, W., Oct. 2015. Risk factors associated with HCV among Opioid-Dependent patients in a multisite study. *J. Community Health* 40 (5), 940–947.
- Simoens, S., Matheson, C., Bond, C., Inkster, K., Ludbrook, A., Feb. 2005. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. *Br. J. Gen. Pract.* 55 (511), 139–146.
- Tai, B., Sparenborg, S., Liu, D., Straus, M., Mar. 2011. The national drug abuse treatment clinical trials network: forging a partnership between research knowledge and community practice. *Subst. Abuse Rehabil.* 2, 21–28.
- Teruya, C., Schwartz, R. P., Mitchell, S. G., Hasson, A. L., Thomas, C., Buoncristiani, S. H., Hser, Y.-I., Wiest, K., Cohen, A. J., Glick, N., Jacobs, P., McLaughlin, P., Ling, W., Nov. 2014. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. *J. Psychoactive Drugs* 46 (5), 412–426.
- Upadhyay, J., Maleki, N., Potter, J., Elman, I., Rudrauf, D., Knudsen, J., Wallin, D., Pendse, G., McDonald, L., Griffin, M., Anderson, J., Nutile, L., Renshaw, P., Weiss, R., Becerra, L., Borsook, D., Jul. 2010. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain* 133 (Pt 7), 2098–2114.
- Weiss, R. D., Griffin, M. L., Marcovitz, D. E., Hilton, B. T., Fitzmaurice, G. M., McHugh, R. K., Carroll, K. M., Mar. 2019. Correlates of opioid abstinence in a 42-month posttreatment naturalistic Follow-Up study of prescription opioid dependence. *J. Clin. Psychiatry* 80 (2).
- Weiss, R. D., Potter, J. S., Copersino, M. L., Prather, K., Jacobs, P., Provost, S., Chim, D., Selzer, J., Ling, W., Mar. 2010a. Conducting clinical research with prescription opioid dependence: defining the population. *Am. J. Addict.* 19 (2), 141–146.
- Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Gourevitch, M. N., Haller, D. L., Hasson, A. L., Huang, Z., Jacobs, P., Kosinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., Sonne, S. C., Ling, W., Dec. 2011. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. *Arch. Gen. Psychiatry* 68 (12), 1238–1246.
- Weiss, R. D., Potter, J. S., Griffin, M. L., McHugh, R. K., Haller, D., Jacobs, P., Gardin, 2nd, J., Fischer, D., Rosen, K. D., Aug. 2014. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. *J. Subst. Abuse Treat.* 47 (2), 140–145.
- Weiss, R. D., Potter, J. S., Griffin, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., Srisarajivakul, E. N., Dodd, D. R., Dreifuss, J. A., McHugh, R. K., Carroll, K. M., May 2015. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction

- treatment study. *Drug Alcohol Depend.* 150, 112–119.
- Weiss, R. D., Potter, J. S., Provost, S. E., Huang, Z., Jacobs, P., Hasson, A., Lindblad, R., Connery, H. S., Prather, K., Ling, W., Mar. 2010b. A multi-site, two-phase, prescription opioid addiction treatment study (POATS): rationale, design, and methodology. *Contemp. Clin. Trials* 31 (2), 189–199.
- Weiss, R. D., Rao, V., Apr. 2017. The prescription opioid addiction treatment study: What have we learned. *Drug Alcohol Depend.* 173 Suppl 1, S48–S54.
- Woody, G. E., Bruce, D., Korthuis, P. T., Chhatre, S., Poole, S., Hillhouse, M., Jacobs, P., Sorensen, J., Saxon, A. J., Metzger, D., Ling, W., Jul. 2014. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. *J. Acquir. Immune Defic. Syndr.* 66 (3), 288–293.
- Worley, M. J., Heinzerling, K. G., Shoptaw, S., Ling, W., Dec. 2015a. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. *Exp. Clin. Psychopharmacol.* 23 (6), 428–435.
- Worley, M. J., Heinzerling, K. G., Shoptaw, S., Ling, W., Jul. 2017. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. *Addiction* 112 (7), 1202–1209.
- Worley, M. J., Shoptaw, S. J., Bickel, W. K., Ling, W., Mar. 2015b. Using behavioral economics to predict opioid use during prescription opioid dependence treatment. *Drug Alcohol Depend.* 148, 62–68.
- Zhu, Y., Evans, E. A., Mooney, L. J., Saxon, A. J., Kelleghan, A., Yoo, C., Hser, Y.-I., Dec. 2018. Correlates of Long-Term opioid abstinence after randomization to methadone versus Buprenorphine/Naloxone in a Multi-Site trial. *J. Neuroimmune Pharmacol.* 13 (4), 488–497.